nodes	percent_of_prediction	percent_of_DWPC	metapath
Azilsartan medoxomil—Hyperuricaemia—Aminophylline—chronic obstructive pulmonary disease	0.0297	0.0347	CcSEcCtD
Azilsartan medoxomil—Blood uric acid increased—Aminophylline—chronic obstructive pulmonary disease	0.028	0.0328	CcSEcCtD
Azilsartan medoxomil—Connective tissue disorder—Roflumilast—chronic obstructive pulmonary disease	0.0204	0.0238	CcSEcCtD
Azilsartan medoxomil—Muscle spasms—Roflumilast—chronic obstructive pulmonary disease	0.0173	0.0203	CcSEcCtD
Azilsartan medoxomil—Angioedema—Roflumilast—chronic obstructive pulmonary disease	0.0165	0.0193	CcSEcCtD
Azilsartan medoxomil—AGTR1—ACE Inhibitor Pathway—ACE—chronic obstructive pulmonary disease	0.0163	0.13	CbGpPWpGaD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Roflumilast—chronic obstructive pulmonary disease	0.0152	0.0178	CcSEcCtD
Azilsartan medoxomil—Nervous system disorder—Roflumilast—chronic obstructive pulmonary disease	0.0144	0.0169	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Roflumilast—chronic obstructive pulmonary disease	0.0143	0.0167	CcSEcCtD
Azilsartan medoxomil—Oedema peripheral—Tiotropium—chronic obstructive pulmonary disease	0.0128	0.015	CcSEcCtD
Azilsartan medoxomil—Connective tissue disorder—Tiotropium—chronic obstructive pulmonary disease	0.0128	0.015	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Roflumilast—chronic obstructive pulmonary disease	0.0127	0.0149	CcSEcCtD
Azilsartan medoxomil—Fatigue—Roflumilast—chronic obstructive pulmonary disease	0.0127	0.0148	CcSEcCtD
Azilsartan medoxomil—Angiopathy—Tiotropium—chronic obstructive pulmonary disease	0.0118	0.0138	CcSEcCtD
Azilsartan medoxomil—Asthenia—Roflumilast—chronic obstructive pulmonary disease	0.0106	0.0124	CcSEcCtD
Azilsartan medoxomil—Angioedema—Tiotropium—chronic obstructive pulmonary disease	0.0104	0.0121	CcSEcCtD
Azilsartan medoxomil—Oedema peripheral—Arformoterol—chronic obstructive pulmonary disease	0.0104	0.0121	CcSEcCtD
Azilsartan medoxomil—Oedema peripheral—Formoterol—chronic obstructive pulmonary disease	0.0104	0.0121	CcSEcCtD
Azilsartan medoxomil—Connective tissue disorder—Formoterol—chronic obstructive pulmonary disease	0.0103	0.0121	CcSEcCtD
Azilsartan medoxomil—Connective tissue disorder—Arformoterol—chronic obstructive pulmonary disease	0.0103	0.0121	CcSEcCtD
Azilsartan medoxomil—Connective tissue disorder—Montelukast—chronic obstructive pulmonary disease	0.0101	0.0118	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Roflumilast—chronic obstructive pulmonary disease	0.0101	0.0118	CcSEcCtD
Azilsartan medoxomil—Connective tissue disorder—Salbutamol—chronic obstructive pulmonary disease	0.00975	0.0114	CcSEcCtD
Azilsartan medoxomil—Dizziness—Roflumilast—chronic obstructive pulmonary disease	0.00973	0.0114	CcSEcCtD
Azilsartan medoxomil—Nervous system disorder—Aminophylline—chronic obstructive pulmonary disease	0.00962	0.0113	CcSEcCtD
Azilsartan medoxomil—Losartan—ACE—chronic obstructive pulmonary disease	0.00959	0.472	CrCbGaD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Tiotropium—chronic obstructive pulmonary disease	0.00959	0.0112	CcSEcCtD
Azilsartan medoxomil—Rash—Roflumilast—chronic obstructive pulmonary disease	0.00928	0.0109	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Roflumilast—chronic obstructive pulmonary disease	0.00927	0.0108	CcSEcCtD
Azilsartan medoxomil—Nervous system disorder—Tiotropium—chronic obstructive pulmonary disease	0.00908	0.0106	CcSEcCtD
Azilsartan medoxomil—Angiopathy—Salbutamol—chronic obstructive pulmonary disease	0.00901	0.0105	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Tiotropium—chronic obstructive pulmonary disease	0.00899	0.0105	CcSEcCtD
Azilsartan medoxomil—Muscle spasms—Formoterol—chronic obstructive pulmonary disease	0.0088	0.0103	CcSEcCtD
Azilsartan medoxomil—Muscle spasms—Arformoterol—chronic obstructive pulmonary disease	0.0088	0.0103	CcSEcCtD
Azilsartan medoxomil—Nausea—Roflumilast—chronic obstructive pulmonary disease	0.00874	0.0102	CcSEcCtD
Azilsartan medoxomil—Muscle spasms—Montelukast—chronic obstructive pulmonary disease	0.00862	0.0101	CcSEcCtD
Azilsartan medoxomil—Angioedema—Formoterol—chronic obstructive pulmonary disease	0.00836	0.00978	CcSEcCtD
Azilsartan medoxomil—Angioedema—Arformoterol—chronic obstructive pulmonary disease	0.00836	0.00978	CcSEcCtD
Azilsartan medoxomil—Muscle spasms—Salbutamol—chronic obstructive pulmonary disease	0.00831	0.00972	CcSEcCtD
Azilsartan medoxomil—Angioedema—Montelukast—chronic obstructive pulmonary disease	0.00819	0.00958	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Tiotropium—chronic obstructive pulmonary disease	0.00799	0.00935	CcSEcCtD
Azilsartan medoxomil—Angioedema—Salbutamol—chronic obstructive pulmonary disease	0.0079	0.00924	CcSEcCtD
Azilsartan medoxomil—AGTR1—Arf6 signaling events—ADRB2—chronic obstructive pulmonary disease	0.0078	0.0624	CbGpPWpGaD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Arformoterol—chronic obstructive pulmonary disease	0.00774	0.00905	CcSEcCtD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Formoterol—chronic obstructive pulmonary disease	0.00774	0.00905	CcSEcCtD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Montelukast—chronic obstructive pulmonary disease	0.00758	0.00887	CcSEcCtD
Azilsartan medoxomil—AGTR1—ACE Inhibitor Pathway—NOS3—chronic obstructive pulmonary disease	0.00756	0.0606	CbGpPWpGaD
Azilsartan medoxomil—Nervous system disorder—Formoterol—chronic obstructive pulmonary disease	0.00732	0.00857	CcSEcCtD
Azilsartan medoxomil—Nervous system disorder—Arformoterol—chronic obstructive pulmonary disease	0.00732	0.00857	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Formoterol—chronic obstructive pulmonary disease	0.00725	0.00849	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Arformoterol—chronic obstructive pulmonary disease	0.00725	0.00849	CcSEcCtD
Azilsartan medoxomil—Nervous system disorder—Montelukast—chronic obstructive pulmonary disease	0.00717	0.00839	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Montelukast—chronic obstructive pulmonary disease	0.00711	0.00831	CcSEcCtD
Azilsartan medoxomil—Pruritus—Aminophylline—chronic obstructive pulmonary disease	0.00694	0.00812	CcSEcCtD
Azilsartan medoxomil—Nervous system disorder—Salbutamol—chronic obstructive pulmonary disease	0.00692	0.00809	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Salbutamol—chronic obstructive pulmonary disease	0.00685	0.00801	CcSEcCtD
Azilsartan medoxomil—AGTR1—Peptide GPCRs—CXCR2—chronic obstructive pulmonary disease	0.00683	0.0547	CbGpPWpGaD
Azilsartan medoxomil—Losartan—CYP1A2—chronic obstructive pulmonary disease	0.00681	0.335	CrCbGaD
Azilsartan medoxomil—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	0.00671	0.00786	CcSEcCtD
Azilsartan medoxomil—Pruritus—Tiotropium—chronic obstructive pulmonary disease	0.00655	0.00766	CcSEcCtD
Azilsartan medoxomil—Dizziness—Aminophylline—chronic obstructive pulmonary disease	0.00649	0.00759	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Formoterol—chronic obstructive pulmonary disease	0.00645	0.00754	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.00645	0.00754	CcSEcCtD
Azilsartan medoxomil—Fatigue—Formoterol—chronic obstructive pulmonary disease	0.00644	0.00753	CcSEcCtD
Azilsartan medoxomil—Fatigue—Arformoterol—chronic obstructive pulmonary disease	0.00644	0.00753	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Montelukast—chronic obstructive pulmonary disease	0.00632	0.00739	CcSEcCtD
Azilsartan medoxomil—Fatigue—Montelukast—chronic obstructive pulmonary disease	0.00631	0.00738	CcSEcCtD
Azilsartan medoxomil—Rash—Aminophylline—chronic obstructive pulmonary disease	0.00619	0.00724	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	0.00618	0.00723	CcSEcCtD
Azilsartan medoxomil—AGTR1—Arf6 trafficking events—ADRB2—chronic obstructive pulmonary disease	0.00616	0.0493	CbGpPWpGaD
Azilsartan medoxomil—Dizziness—Tiotropium—chronic obstructive pulmonary disease	0.00612	0.00716	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.00609	0.00712	CcSEcCtD
Azilsartan medoxomil—Fatigue—Salbutamol—chronic obstructive pulmonary disease	0.00608	0.00711	CcSEcCtD
Azilsartan medoxomil—Rash—Tiotropium—chronic obstructive pulmonary disease	0.00584	0.00683	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	0.00583	0.00682	CcSEcCtD
Azilsartan medoxomil—Nausea—Aminophylline—chronic obstructive pulmonary disease	0.00583	0.00682	CcSEcCtD
Azilsartan medoxomil—AGTR1—Allograft Rejection—IL13—chronic obstructive pulmonary disease	0.00574	0.046	CbGpPWpGaD
Azilsartan medoxomil—Nausea—Tiotropium—chronic obstructive pulmonary disease	0.0055	0.00643	CcSEcCtD
Azilsartan medoxomil—Asthenia—Formoterol—chronic obstructive pulmonary disease	0.00536	0.00627	CcSEcCtD
Azilsartan medoxomil—Asthenia—Arformoterol—chronic obstructive pulmonary disease	0.00536	0.00627	CcSEcCtD
Azilsartan medoxomil—Pruritus—Formoterol—chronic obstructive pulmonary disease	0.00528	0.00618	CcSEcCtD
Azilsartan medoxomil—Pruritus—Arformoterol—chronic obstructive pulmonary disease	0.00528	0.00618	CcSEcCtD
Azilsartan medoxomil—AGTR1—Allograft Rejection—IL17A—chronic obstructive pulmonary disease	0.00528	0.0423	CbGpPWpGaD
Azilsartan medoxomil—Asthenia—Montelukast—chronic obstructive pulmonary disease	0.00525	0.00614	CcSEcCtD
Azilsartan medoxomil—Pruritus—Montelukast—chronic obstructive pulmonary disease	0.00518	0.00606	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	0.00511	0.00598	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	0.00511	0.00598	CcSEcCtD
Azilsartan medoxomil—Asthenia—Salbutamol—chronic obstructive pulmonary disease	0.00506	0.00592	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	0.00501	0.00586	CcSEcCtD
Azilsartan medoxomil—AGTR1—ACE Inhibitor Pathway—TGFB1—chronic obstructive pulmonary disease	0.005	0.0401	CbGpPWpGaD
Azilsartan medoxomil—Pruritus—Salbutamol—chronic obstructive pulmonary disease	0.00499	0.00584	CcSEcCtD
Azilsartan medoxomil—Dizziness—Formoterol—chronic obstructive pulmonary disease	0.00494	0.00578	CcSEcCtD
Azilsartan medoxomil—Dizziness—Arformoterol—chronic obstructive pulmonary disease	0.00494	0.00578	CcSEcCtD
Azilsartan medoxomil—Dizziness—Montelukast—chronic obstructive pulmonary disease	0.00484	0.00566	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	0.00483	0.00565	CcSEcCtD
Azilsartan medoxomil—Rash—Formoterol—chronic obstructive pulmonary disease	0.00471	0.00551	CcSEcCtD
Azilsartan medoxomil—Rash—Arformoterol—chronic obstructive pulmonary disease	0.00471	0.00551	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	0.00471	0.0055	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Formoterol—chronic obstructive pulmonary disease	0.00471	0.0055	CcSEcCtD
Azilsartan medoxomil—Dizziness—Salbutamol—chronic obstructive pulmonary disease	0.00466	0.00546	CcSEcCtD
Azilsartan medoxomil—Rash—Montelukast—chronic obstructive pulmonary disease	0.00461	0.0054	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Montelukast—chronic obstructive pulmonary disease	0.00461	0.00539	CcSEcCtD
Azilsartan medoxomil—Angioedema—Prednisolone—chronic obstructive pulmonary disease	0.00453	0.0053	CcSEcCtD
Azilsartan medoxomil—Rash—Salbutamol—chronic obstructive pulmonary disease	0.00445	0.0052	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	0.00444	0.0052	CcSEcCtD
Azilsartan medoxomil—Nausea—Formoterol—chronic obstructive pulmonary disease	0.00444	0.00519	CcSEcCtD
Azilsartan medoxomil—Nausea—Arformoterol—chronic obstructive pulmonary disease	0.00444	0.00519	CcSEcCtD
Azilsartan medoxomil—Nausea—Montelukast—chronic obstructive pulmonary disease	0.00435	0.00508	CcSEcCtD
Azilsartan medoxomil—Nausea—Salbutamol—chronic obstructive pulmonary disease	0.00419	0.0049	CcSEcCtD
Azilsartan medoxomil—Connective tissue disorder—Prednisone—chronic obstructive pulmonary disease	0.00407	0.00476	CcSEcCtD
Azilsartan medoxomil—Losartan—ALB—chronic obstructive pulmonary disease	0.00393	0.193	CrCbGaD
Azilsartan medoxomil—Angiopathy—Prednisone—chronic obstructive pulmonary disease	0.00375	0.00439	CcSEcCtD
Azilsartan medoxomil—AGTR1—Allograft Rejection—IL10—chronic obstructive pulmonary disease	0.00359	0.0288	CbGpPWpGaD
Azilsartan medoxomil—Angioedema—Prednisone—chronic obstructive pulmonary disease	0.00329	0.00385	CcSEcCtD
Azilsartan medoxomil—AGTR1—Peptide ligand-binding receptors—CXCR2—chronic obstructive pulmonary disease	0.00321	0.0257	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Angiopoietin receptor Tie2-mediated signaling—NOS3—chronic obstructive pulmonary disease	0.00319	0.0256	CbGpPWpGaD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Prednisone—chronic obstructive pulmonary disease	0.00305	0.00356	CcSEcCtD
Azilsartan medoxomil—Nervous system disorder—Prednisone—chronic obstructive pulmonary disease	0.00288	0.00337	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Prednisone—chronic obstructive pulmonary disease	0.00286	0.00334	CcSEcCtD
Azilsartan medoxomil—AGTR1—Arf6 signaling events—EGFR—chronic obstructive pulmonary disease	0.00275	0.022	CbGpPWpGaD
Azilsartan medoxomil—Dizziness—Prednisolone—chronic obstructive pulmonary disease	0.00267	0.00313	CcSEcCtD
Azilsartan medoxomil—Rash—Prednisolone—chronic obstructive pulmonary disease	0.00255	0.00298	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	0.00255	0.00298	CcSEcCtD
Azilsartan medoxomil—Fatigue—Prednisone—chronic obstructive pulmonary disease	0.00253	0.00296	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCRs, Class A Rhodopsin-like—CXCR2—chronic obstructive pulmonary disease	0.00251	0.0201	CbGpPWpGaD
Azilsartan medoxomil—Nausea—Prednisolone—chronic obstructive pulmonary disease	0.0024	0.00281	CcSEcCtD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—CXCR2—chronic obstructive pulmonary disease	0.00215	0.0172	CbGpPWpGaD
Azilsartan medoxomil—Asthenia—Prednisone—chronic obstructive pulmonary disease	0.00211	0.00247	CcSEcCtD
Azilsartan medoxomil—Pruritus—Prednisone—chronic obstructive pulmonary disease	0.00208	0.00243	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	0.00201	0.00235	CcSEcCtD
Azilsartan medoxomil—AGTR1—Angiopoietin receptor Tie2-mediated signaling—TNF—chronic obstructive pulmonary disease	0.00197	0.0158	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Allograft Rejection—CXCL8—chronic obstructive pulmonary disease	0.00196	0.0157	CbGpPWpGaD
Azilsartan medoxomil—Dizziness—Prednisone—chronic obstructive pulmonary disease	0.00194	0.00227	CcSEcCtD
Azilsartan medoxomil—AGTR1—Allograft Rejection—IL1B—chronic obstructive pulmonary disease	0.00188	0.0151	CbGpPWpGaD
Azilsartan medoxomil—Rash—Prednisone—chronic obstructive pulmonary disease	0.00185	0.00217	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Prednisone—chronic obstructive pulmonary disease	0.00185	0.00217	CcSEcCtD
Azilsartan medoxomil—AGTR1—G alpha (q) signalling events—EDN1—chronic obstructive pulmonary disease	0.00182	0.0146	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Peptide ligand-binding receptors—EDN1—chronic obstructive pulmonary disease	0.0018	0.0144	CbGpPWpGaD
Azilsartan medoxomil—Nausea—Prednisone—chronic obstructive pulmonary disease	0.00175	0.00204	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—CXCR2—chronic obstructive pulmonary disease	0.00164	0.0131	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—chronic obstructive pulmonary disease	0.00163	0.0131	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—G alpha (q) signalling events—HTR2A—chronic obstructive pulmonary disease	0.00159	0.0128	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Allograft Rejection—VEGFA—chronic obstructive pulmonary disease	0.00159	0.0128	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCRs, Class A Rhodopsin-like—ADRB2—chronic obstructive pulmonary disease	0.00158	0.0126	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Allograft Rejection—TGFB1—chronic obstructive pulmonary disease	0.00146	0.0117	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—chronic obstructive pulmonary disease	0.00143	0.0114	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Allograft Rejection—TNF—chronic obstructive pulmonary disease	0.00137	0.0109	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—ADRB2—chronic obstructive pulmonary disease	0.00135	0.0108	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—FAM13A—chronic obstructive pulmonary disease	0.00134	0.0108	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCRs, Class A Rhodopsin-like—HTR2A—chronic obstructive pulmonary disease	0.00123	0.00987	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—EDN1—chronic obstructive pulmonary disease	0.00121	0.00967	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—PDE4A—chronic obstructive pulmonary disease	0.00115	0.00921	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—HTR2A—chronic obstructive pulmonary disease	0.00106	0.00846	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—PDE4A—chronic obstructive pulmonary disease	0.00104	0.00836	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—ADRB2—chronic obstructive pulmonary disease	0.00103	0.00824	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Peptide ligand-binding receptors—CXCL8—chronic obstructive pulmonary disease	0.000973	0.00779	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	0.000927	0.00742	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	0.000919	0.00736	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	0.000842	0.00674	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	0.000814	0.00652	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	0.000804	0.00644	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	0.000653	0.00523	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—chronic obstructive pulmonary disease	0.000644	0.00516	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	0.000617	0.00494	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	0.000581	0.00466	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	0.000528	0.00423	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	0.00052	0.00416	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	0.000497	0.00398	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	0.000497	0.00398	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—chronic obstructive pulmonary disease	0.000495	0.00396	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	0.000472	0.00378	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	0.000455	0.00364	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	0.000413	0.00331	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	0.000364	0.00291	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—KL—chronic obstructive pulmonary disease	0.000338	0.00271	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	0.000312	0.0025	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	0.000281	0.00225	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	0.000279	0.00223	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	0.000255	0.00204	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	0.000253	0.00203	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	0.000244	0.00195	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—LEP—chronic obstructive pulmonary disease	0.000227	0.00182	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	0.000186	0.00149	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	0.000178	0.00142	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	0.00017	0.00136	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	0.000151	0.00121	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	0.000143	0.00115	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	0.000136	0.00109	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	0.000122	0.00098	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	0.000112	0.000899	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	0.00011	0.000882	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—TP53—chronic obstructive pulmonary disease	9.24e-05	0.00074	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—IL6—chronic obstructive pulmonary disease	8.46e-05	0.000678	CbGpPWpGaD
